

## HPTN NL Communique # 2

HPTN 052

SSP section 10: Laboratory Procedures, version 1.6

**This is official study documentation for the HPTN 052 trial. Please circulate it among relevant staff for their review, print it out, and place it at the end of your 052 SSP Manual, Section 10: Laboratory Communiques.**

Date: September 14, 2009

**This communique consists of a clarification to the SSP, two corrections to the SSP (version 1.6), an update, and several laboratory reminders. The SSP will be updated when we release the new version of the SSP. New text is bolded; deleted text is marked with a strikethrough of the wording.**

### 1. Clarification:

**Table 1**

Laboratory Assay	Performance Site	Specific Kit, Procedure, or Instrument
<b>HIV/AIDS Related Assays</b>		
HIV EIA Antibody Test	All sites	Rapid Testing: Trinity Biotech Uni-Gold® or Oraquick®, or Bio-Rad EIA, and Western Blot Kit or alternative HIV test kit (Rapid, EIA, WB/IFA) approved by the U.S. FDA. <u>A list of approved kits can be found online at: <a href="http://www.fda.gov/cber/products/testkits.htm">http://www.fda.gov/cber/products/testkits.htm</a></u>
HIV Western Blot (Confirmatory)	Sites may use either Western Blot or IFA	Bio-Rad Western Blot Kit or alternative HIV WB or IFA test kit approved by the U.S. FDA. <u>A list of approved kits can be found online at: <a href="http://www.fda.gov/cber/products/testkits.htm">http://www.fda.gov/cber/products/testkits.htm</a></u>
HIV IFA (Confirmatory)		Fluorognost HIV-1 IFA

#### 10.2.1 HIV Antibody Testing Algorithm

~~However, sites may use their own, validated HIV antibody testing algorithm for screening as long as U.S. FDA approved test kits are used. If an alternative HIV testing algorithm is used for screening, it must be contained in the site's HIV antibody testing (HIV EIA antibody test/Western blot/IFA) SOP and approved by the HPTN NL.~~

**The requirements outlined below must be followed for sites using rapid HIV tests at screening for eligibility for the Index Case and Partner, and for Partner follow-up:**

- **If only one rapid HIV test is used, the test must be U.S. FDA-approved. If positive, a Western Blot or IFA must be performed using a U.S. FDA-approved test to confirm the result.**
- **If two rapid HIV tests are used, one of them must be U.S. FDA-approved. If positive or discordant, a Western Blot or IFA must be performed using a U.S. FDA-approved test to confirm the result.**
- **If two rapid HIV tests are used in parallel where a third rapid HIV test is used as a tie-breaker, one of the two tests run in parallel MUST be U.S. FDA-approved. Please note the following:**
  - **If the results of the parallel rapid HIV testing are discordant and the U.S. FDA-approved test is the negative result, and the tie-breaker result is also negative, no further testing is required.**
  - **If the results of the parallel rapid HIV testing are discordant and the U.S. FDA approved test is the positive result, a tie-breaker test is not necessary(though a site may have to perform one based on their site-specific requirements), and a HIV Western Blot test must be performed using a U.S. FDA-approved test.**
- **If HIV ELISA testing is used, the test must be U.S. FDA approved. If positive, a Western Blot or IFA must be performed using a U.S. FDA-approved test to confirm the result.**
- **If a combination of rapid HIV tests and HIV ELISA is used, the algorithm must be reviewed and approved by the HPTN Network Laboratory to ensure that the site is using U.S. FDA-approved tests.**

**Finally, in the event that a negative partner seroconverts at any time during follow-up, sites must follow the HIV antibody testing algorithm outlined in Appendix II of the protocol to confirm HIV status.**

Detailed in Table 1 and section 10.2.1 is information on the use of US FDA- approved test kits for HIV-1 testing in HPTN 052. The FDA web site is updated periodically and should be checked on a routine basis to ensure that the kits in use on site are still available and FDA cleared. Several companies offer two versions of the kits: one that is available internationally that is not FDA approved and one that is FDA approved. Two of the FDA approved assays are Trinity Biotech Uni-Gold™ Recombigen® and OraQuick *ADVANCE*® Rapid HIV-1/2 Antibody Test. These are assigned different catalog numbers than the non-FDA approved kits. There are

several other FDA approved kits available. Sites should check the FDA list quarterly for any updates and check with the Network Laboratory regarding any rapid test kit, EIA or WB kit in use. Any changes in kit methodology must be validated and approved by the NL.

Table 1 will be updated with the removal of the names of the kits and will state:

**Rapid Testing: A rapid HIV test or HIV ELISA test that has been approved by the FDA.**

**A list of approved kits can be found online at:**

**<http://www.fda.gov/cber/products/testkits.htm>**

## **2. Correction**

a. The following section will be updated with the new information regarding the Cross Network SOP for PBMC preparation.

### **10.6.4 PBMC**

Archived plasma and PBMCs samples will come from the same 10 mL blood sample collected using an EDTA (lavender top) tube (see Table 10-3). The blood should be processed within 30 hours of sample collection. Either the Ficoll-Hypaque Underlay or Overlay Methods (density-gradient centrifugation techniques) will be used to process the PBMC sample. Refer to ~~the Joint HPTN-MTN laboratory manual for instructions on processing PBMCs following the Cross-network SOP found on the following HANC website.~~

~~<http://www.hptn.org/web%20documents/CentralLab/HPTN-MTNLABMANUALVersion1.0.pdf> pages 413-461~~

~~or HANC website : <http://www.hanc.info/Pages/index.aspx>~~

**<http://www.hanc.info/labs/Pages/PBMC SOP.aspx>**

b. The following section will be updated with new information regarding Fetal Bovine Serum ordering.

### **10.12.3 Fetal Bovine Serum Ordering Information**

Bottles (500 ml) of validated heat inactivated Fetal Bovine Serum (FBS) have been placed on reserve. ~~with Gemini Bio Products ([www.gembio.com](http://www.gembio.com)).~~ The reserve lots of FBS have been validated by the DAIDS-sponsored Virology Quality Assurance (VQA) Laboratory **and Immunology Quality Assurance (IQA) laboratory** for use in culture experiments and for **Peripheral Blood Mononuclear Cell (PBMC) cryopreservation. The results of the VQA and IQA validation testing have been posted to the web at**

**<http://www.hanc.info/labs/Pages/FBSOrdering.aspx>. The company's certificate of analysis of the lot is available upon request.**

~~the analysis results are available on the web at <http://aactg.s-3.com/vqareports.htm>. The company's certificate of analysis of each lot is available upon request.~~

~~Please have the following information ready when placing your order:~~

Phone: 1-800-543-6464, Ext. 104 for customer service (for U.S. sites)

———1-530-668-3636 (for international sites)

Fax: —1-530-668-3630

Quotation number

Customer number

Lot number

The most current quotation number, customer number, and lot number, as well as other information related to fetal bovine serum, can be found at

[http://www.hptn.org/research\\_studies/HPTN052Lab.htm](http://www.hptn.org/research_studies/HPTN052Lab.htm).

[http://www.hptn.org/research\\_studies/HPTN052Lab.asp#FBSOrdering](http://www.hptn.org/research_studies/HPTN052Lab.asp#FBSOrdering). **Please check this website before ordering for additional information.**

If you have any specific questions relating to the FBS, please contact John Polan at Gemini Bio-Products at 1-800-543-6464 ext. 302, 1-530-668-3636, or via email at [jpolan@gembio.com](mailto:jpolan@gembio.com), the customer service department at 1-800-543-6464 ext 104, or consult your affiliate U.S. institution if you are having trouble obtaining this item.

### 3. Update

FSTRF has an updated version of the LDMS user's manual available on the following website

**<https://www.fstrf.org/apps/cfm/apps/ldms/manual/manual.html>**

#### **Reminders**

- a. Each site is responsible for submitting monthly laboratory quality control (QC) reports for their safety laboratory tests to the HPTN NL. These reports should contain the site's monthly Levey Jennings plots and corrective actions, if applicable. Contact Estelle Piwowa-Manning ([epiwowa@jhmi.edu](mailto:epiwowa@jhmi.edu)) to determine the required content and format of your site's report.
- b. Laboratory inventory must be provided to the Network laboratory on a monthly (or as determined with the NL). Details regarding the inventory are available at [http://www.hptn.org/research\\_studies/HPTN052Lab.asp#LabInventory](http://www.hptn.org/research_studies/HPTN052Lab.asp#LabInventory)
- c. Each site should have a LDMS CRF weekly reconciliation document in place to resolve any missing samples. Each site is reminded to export their LDMS data to FSTRF on a weekly or more frequent basis. Exported data are use by the HPTN SDMC to generate a monthly specimen repository report and to reconcile data entered in LDMS with data entered on study case report forms. Any discrepancies identified during the reconciliation are included in a monthly discrepancy report for each site. Sites are expected to resolve all discrepancies within two weeks of receipt of the report.